AzTrials
AzTrials

AneurysmPANTHERNCT04545502

PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

An observational study of Aneurysm and Dissection, run by Vascutek Ltd. at 30 sites in 6 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice. Data will be collected both retrospectively and prospectively. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Aneurysm, Dissection, Aortic Root Aneurysm
What is being tested?
Gelsoft Plus Vascular Graft, Vascular Bypass Graft and Cardiovascular Patch
Type of treatment
Medical device
How many people
2,000 participants
Where
30 sitesin 6 countries
Study dates
17 Feb 2021to Jan 2037
How long will I take part?
10 Years
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who require treatment, or have already received treatment within the last 5 years, with the following commercially available Terumo Aortic knitted and woven grafts and cardiovascular patches: * Gelsoft Plus - Straights and Bifurcated * Gelsoft Plus - Extra-Anatomical * Cardiovascular Patches - Gelseal, Gelsoft and Thin Wall * Gelweave - Abdominal, Thoracic and Thoracoabdominal * Gelweave - Valsalva This is a non-interventional study and therefore only patients who would normally receive treatment with a Terumo Aortic devices as part of standard treatment at the participating institution can be enrolled.

Who may be able to join

  • Patients must meet all of the following inclusion criteria in order to be eligible for inclusion in the study:
  • All Patients:
  • Patient meets the minimum age as per local regulations at time of consent
  • Patient requires treatment with study device(s) according to the IFU(s)
  • Patient is willing and able to comply with all SOC procedures and study visits
  • Patient or their legally authorised representative (LAR) has given written informed consent to participate in study, including consent to collect data retrospectively
Show all 11Show fewer
  • For prospective emergency patients, retrospective consent is permissible
  • For retrospective patients who are deceased at time of enrollment, local EC regulations relating to consent process should be followed.
  • Retrospective Patients only:
  • Patient has a minimum of 1 year post-operative follow-up data available, or complete data to death.
  • Patient implant date is no more than 5 years prior to study start date.

Who cannot join

  • Any patient who meets any of the following exclusion criteria will be excluded from participation in the study:
  • Patient is unable or unwilling to comply with the SOC procedures or follow-up regime
  • Patient is contraindicated per the device IFU
  • Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post-procedure

Trial locations and contacts

30 sites in 6 countries. Contact the study team or a site near you to ask about taking part.

30 sites in 6 countries

United States10 sites, 10 recruiting
  • Lehigh Valley Hospital

    Allentown, Pennsylvania, 18103

    James Wu, James.Wu@lvhn.org

    James Wu

    Recruiting
  • University of Colorado Anschutz

    Aurora, Colorado, 80045

    Brett Reece

    Brett Reece

    Recruiting
  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106

    Terence Semenec, terence.semenec@UHhospitals.org

    Jae Cho

    Recruiting
  • Ohio State University

    Columbus, Ohio, 43210

    Kristine Orion

    Kristine Orion

    Recruiting
  • Duke University

    Durham, North Carolina, 27705

    Chad Hughes, gchad.hughes@duke.edu

    Chad Hughes

    Recruiting
  • East Carolina University

    Greenville, North Carolina, 27858

    Eddie Hill, Hille19@ecu.edu

    Benjamin Degner

    Recruiting
  • Indiana University Health

    Indianapolis, Indiana, 46202

    Joel Corvera, MD, jcorvera@iuhealth.org

    Joel Corvera

    Recruiting
  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19105

    Eric Suchanec, Eric.Suchanec@Pennmedicine.upenn.edu

    Nimesh Desai

    Recruiting
  • Virginia Commonwealth University

    Richmond, Virginia, 23298

    Daniel Newton, MD, daniel.newton@vcuhealth.org

    Daniel Newton

    Recruiting
  • University of South Florida - Tampa General

    Tampa, Florida, 33620

    Thanh Tran, tqtran@usf.edu

    Murray Shames

    Recruiting

Other trials in United States

France8 sites, 6 recruiting
  • CHU Bordeaux

    Bordeaux

    Withdrawn
  • CHU Clermont Ferrand

    Clermont-Ferrand

    Valerie Batel, vbatel@chu-clermontferrand.fr

    Thaveau

    Recruiting
  • CHU de Dijon

    Dijon

    Olivier Bouchot

    Olivier Bouchot

    Recruiting
  • CHU de Lille

    Lille, 59000

    Mohamad Koussa

    Mohamad Koussa

    Recruiting
  • Hôpital Nord Marseille

    Marseille, 13015

    Yves Alimi

    Yves Alimi

    Recruiting
  • CHU de Rennes

    Rennes, 35033

    Withdrawn
  • Hôpitaux Universitaires de Strasbourg - Hôpital Civil

    Strasbourg, 67091

    Nabil Chakfe

    Nabil Chakfe

    Recruiting
  • CHU de Toulouse - Hôpital Rangueil

    Toulouse, 31059

    Xavier Chaufour

    Xavier Chaufour

    Recruiting

Other trials in France

Germany7 sites, 7 recruiting
  • Charité Berlin

    Berlin, 12200

    Irene Hinterseher, gefaesschirurgie@charite.de

    Irene Hinterseher

    Recruiting
  • Uniklinik Bonn

    Bonn, 53127

    Marwan Hamiko, marwan.hamiko@ukbonn.de

    Marwan Hamiko

    Recruiting
  • UNIVERSITÄTSKLINIKUM FREIBURG/Bad Krozingen

    Freiburg im Breisgau

    Gabriele Lechner, gabriele.lechner@uniklinik-freiburg.de

    Martin Czerny

    Recruiting
  • UKE Hamburg

    Hamburg, 20251

    Sebastian Debus, s.debus@uke.de

    Sebastian Debus

    Recruiting
  • Heart Center Leipzig

    Leipzig

    Michael Borger

    Michael Borger

    Recruiting
  • Universitätsmedizin Mainz (University Hospital Mainz)

    Mainz, 55131

    Hazem El Beyrouti

    Hazem El Beyrouti

    Recruiting
  • Ludwig-Maximilian Universität (LMU) Klinikum

    Munich, 81377

    Joscha Buch, joscha.buech@med.uni-muenchen.de

    Sven Peterss

    Recruiting

Other trials in Germany

Belgium3 sites, 3 recruiting
  • UZ Gent

    Ghent, 9000

    Nathalie Moreels, nathalie.moreels@uzgent.be

    Nathalie Moreels

    Recruiting
  • AZ Groeninge Kortrijk

    Kortrijk, 8500

    Philip Lerut, philip.lerut@azgroeninge.be

    Philip Lerut

    Recruiting
  • UZ Leuven

    Leuven, 3000

    Peter Verbrugghe, peter.verbrugghe@uzleuven.be

    Peter Verbrugghe

    Recruiting

Other trials in Belgium

Hungary1 site
  • Semmelweis University Heart and Vascular Center

    Budapest, Budapest, 1122

    Completed

Other trials in Hungary

Netherlands1 site
  • Amphia Hospital (Ziekenhuis) Breda

    Breda, 4818

    Active, not recruiting

Other trials in Netherlands

About this study

Official title: A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice.

Data will be collected both retrospectively and prospectively.

Being tested
Gelsoft Plus Vascular Graft, Vascular Bypass Graft, Cardiovascular Patch, Gelweave Vascular Graft, Gelweave Valsalva Vascular Graft
Keywords
Vascular Surgery
Medical subject headings
Aneurysm, Aortic Root Aneurysm, Dissection, Ascending Aorta, Carotid Artery Injuries, Aortic Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gelsoft Plus Vascular GraftDevice

    Also called Gelsoft Plus

    Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.

  • Vascular Bypass GraftDevice

    Also called Gelsoft Plus Extra Anatomical

    Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.

  • Cardiovascular PatchDevice

    Also called Gelseal Patch, Gelsoft Patch, Thinwall Patch, Cardiovascular Fabrics

    Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.

  • Gelweave Vascular GraftDevice

    Also called Gelweave

    The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.

  • Gelweave Valsalva Vascular GraftDevice

    Also called Gelweave Valsalva

    This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.

Study groups in NCT04545502
Study groupRoleWhat they receive
Gelsoft Plus - Straights and BifurcatedPatients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.
Receives: Device: Gelsoft Plus Vascular Graft
Gelsoft Plus - Extra-AnatomicalAny patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.
Receives: Device: Vascular Bypass Graft
Cardiovascular Patches - Gelseal, Gelsoft, Thin WallPatients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.
Receives: Device: Cardiovascular Patch
Gelweave - Abdominal, Thoracic, ThoracoabdominalPatients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards: * Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries. * Thoracic aorta or arteries arising from the thoracic aorta. * Abdominal and thoracic aorta requiring a thoracoabdominal repair
Receives: Device: Gelweave Vascular Graft
Gelweave - ValsalvaPatients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.
Receives: Device: Gelweave Valsalva Vascular Graft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Operative Death

    30 Day or In-Hospital Mortality

    Measured: 1 Year

  2. Graft Leakage

    Device Failure: The presence of leakage or excessive bleeding through graft/patch

    Measured: 1 Year

Secondary outcomes (3)
  1. Device Endpoints

    Device failures, requirement for reintervention or device related adverse events

    Measured: 1 Year

  2. Procedural Endpoints

    Rifampicin or heparin soaking, procedure related adverse events

    Measured: 1 Year

  3. Safety Endpoints

    Occurrence of the following: Mortality, Ischemia, Occlusion, Thrombosis, Haemmorrhage, Rupture, Pseudoaneurysm, Stroke

    Measured: 1 Year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Sep 2020
  2. Study start17 Feb 2021
  3. Primary completionAug 2028 (estimated)
  4. Study completionJan 2037 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
2,000 participants (estimated)
Target duration
10 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT04545502
Sponsor's protocol ID
PANTHER-001
Acronym
PANTHER
Status last verified
Aug 2026
First submitted
3 Sep 2020
Last updated
20 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in